We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Suffers a Larger Drop Than the General Market: Key Insights
Read MoreHide Full Article
Eli Lilly (LLY - Free Report) closed at $1,157.08 in the latest trading session, marking a -2.33% move from the prior day. The stock's change was less than the S&P 500's daily loss of 0.25%. At the same time, the Dow lost 0.86%, and the tech-heavy Nasdaq gained 0.24%.
Heading into today, shares of the drugmaker had gained 2.12% over the past month, outpacing the Medical sector's loss of 1.01% and the S&P 500's loss of 0.42%.
Market participants will be closely following the financial results of Eli Lilly in its upcoming release. The company plans to announce its earnings on October 29, 2026. The company's earnings per share (EPS) are projected to be $9.83, reflecting a 40.03% increase from the same quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $22.08 billion, indicating a 25.46% growth compared to the corresponding quarter of the prior year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $36.66 per share and a revenue of $88.86 billion, signifying shifts of +51.43% and +36.33%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Eli Lilly. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.86% increase. Right now, Eli Lilly possesses a Zacks Rank of #3 (Hold).
In terms of valuation, Eli Lilly is presently being traded at a Forward P/E ratio of 32.31. This denotes a premium relative to the industry average Forward P/E of 16.43.
It is also worth noting that LLY currently has a PEG ratio of 1.45. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.09 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 107, placing it within the top 44% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
View the Zacks #1 Rank List
Image: Bigstock
Eli Lilly (LLY) Suffers a Larger Drop Than the General Market: Key Insights
Eli Lilly (LLY - Free Report) closed at $1,157.08 in the latest trading session, marking a -2.33% move from the prior day. The stock's change was less than the S&P 500's daily loss of 0.25%. At the same time, the Dow lost 0.86%, and the tech-heavy Nasdaq gained 0.24%.
Heading into today, shares of the drugmaker had gained 2.12% over the past month, outpacing the Medical sector's loss of 1.01% and the S&P 500's loss of 0.42%.
Market participants will be closely following the financial results of Eli Lilly in its upcoming release. The company plans to announce its earnings on October 29, 2026. The company's earnings per share (EPS) are projected to be $9.83, reflecting a 40.03% increase from the same quarter last year. In the meantime, our current consensus estimate forecasts the revenue to be $22.08 billion, indicating a 25.46% growth compared to the corresponding quarter of the prior year.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $36.66 per share and a revenue of $88.86 billion, signifying shifts of +51.43% and +36.33%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Eli Lilly. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits.
Research indicates that these estimate revisions are directly correlated with near-term share price momentum. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has witnessed a 0.86% increase. Right now, Eli Lilly possesses a Zacks Rank of #3 (Hold).
In terms of valuation, Eli Lilly is presently being traded at a Forward P/E ratio of 32.31. This denotes a premium relative to the industry average Forward P/E of 16.43.
It is also worth noting that LLY currently has a PEG ratio of 1.45. Comparable to the widely accepted P/E ratio, the PEG ratio also accounts for the company's projected earnings growth. The Large Cap Pharmaceuticals industry currently had an average PEG ratio of 2.09 as of yesterday's close.
The Large Cap Pharmaceuticals industry is part of the Medical sector. At present, this industry carries a Zacks Industry Rank of 107, placing it within the top 44% of over 250 industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.